Pharma-Bio Serv, Inc. (OTCQB:PBSV) announced its financial results for the quarter ended July 31, 2026, in a press release filed with the SEC on September 14, 2026. The company reported that revenues for the three and nine months ended July 31, 2026, were approximately $2.3 million and $7.3 million, respectively. These figures represent increases of approximately $0.4 million and $0.5 million compared to the same periods in the prior year.
In terms of profitability, the company reported a net loss of $14 thousand for the three months ended July 31, 2026. However, for the nine months ended July 31, 2026, the company reported net income of approximately $252 thousand. The company noted that this net income represents an improvement of approximately $352 thousand compared to the corresponding nine-month period of the prior year.
Pharma-Bio Serv provides regulatory compliance consulting services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food, and allied products industries. The company serves markets in Puerto Rico, the United States, Europe, and Brazil. The press release included a statement from Victor Sanchez, the Chief Executive Officer, who highlighted the strength of client relationships and the value of the company’s specialized regulatory capabilities.
